StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research note issued to investors on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Akari Therapeutics Stock Performance
NASDAQ:AKTX opened at $3.01 on Tuesday. Akari Therapeutics has a 52 week low of $1.08 and a 52 week high of $4.40. The company has a fifty day simple moving average of $3.43 and a two-hundred day simple moving average of $2.64.
Akari Therapeutics Company Profile
Featured Articles
- Five stocks we like better than Akari Therapeutics
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- The 3 Best Retail Stocks to Shop for in August
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.